olmesartan has been researched along with hydroxyproline in 3 studies
Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (hydroxyproline) | Trials (hydroxyproline) | Recent Studies (post-2010) (hydroxyproline) |
---|---|---|---|---|---|
841 | 185 | 554 | 10,942 | 334 | 1,426 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujimura, M; Ichikawa, Y; Inuzuka, K; Nakao, S; Nishizawa, Y; Tagami, A; Takato, H; Waseda, Y; Yasui, M | 1 |
Kato, M; Mizuno, M; Sada, T; Terashima, H; Tsuchida, H; Yasumo, H | 1 |
El-kashef, HA; Ibrahim, TM; Shaaban, AA; Shaker, ME; Zalata, KR | 1 |
3 other study(ies) available for olmesartan and hydroxyproline
Article | Year |
---|---|
Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Bleomycin; Blood Cell Count; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Hydroxyproline; Imidazoles; Macrophage Inflammatory Proteins; Male; Mice; Mice, Inbred ICR; Pulmonary Fibrosis; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Tumor Necrosis Factor-alpha; Vasoconstrictor Agents | 2008 |
A sensitive short-term evaluation of antifibrotic effects using newly established type I collagen reporter transgenic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzamides; Collagen; Collagen Type I; Collagen Type I, alpha 1 Chain; Dioxoles; Disease Models, Animal; Fibrosis; Genes, Reporter; Hydroxyproline; Imidazoles; Kidney; Luciferases; Male; Protein Serine-Threonine Kinases; Rats; Rats, Transgenic; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Sensitivity and Specificity; Tetrazoles; Ureteral Obstruction | 2010 |
Modulation of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis by olmesartan and omega-3.
Topics: Actins; Animals; Biomarkers; Carbon Tetrachloride; Drug Therapy, Combination; Fatty Acids, Omega-3; Hydroxyproline; Imidazoles; Liver; Liver Cirrhosis, Experimental; Male; Oxidative Stress; Rats; Rats, Wistar; Receptor, Platelet-Derived Growth Factor beta; Tetrazoles; Transforming Growth Factor beta1 | 2014 |